THE PROGRAM

08:00

Registration and Morning Refreshments

09:00

Welcome Address

09:15

Keynote Lecture

Mark A. Kay, Stanford University, USA

Unraveling the adenoassociated viral capsid ​

10:00

Shulamit Levenberg, Technion, Israel

Engineered skeletal muscle constructs overexpressing GLUT4 for type 2 diabetes treatment

10:20

Rotem Karni, The Hebrew University of Jerusalem, Israel

Modulating RNA processing for therapy

10:40

Batsheva Kerem, The Hebrew University of Jerusalem, Israel

Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach

11:00

Coffee Break

11:30

Eyal Banin, The Hebrew University of Jerusalem / Hadassah Medical Center, Israel

Gene Augmentation Therapy for Achromatopsia Caused by Mutations in the CNGA3 Gene: The Journey from Molecular Genetics to Clinical Application

11:50

Orit Shefi, Bar-Ilan University, Israel

Neuro-engineering tools for nerve regeneration ​

12:10

Lior Gepstein, Technion, Israel

Gene and cell therapy approaches for cardiac disorders​

12:30

GenScript

12:50

Short talks – selected abstracts

13:30

Lunch and Poster Session

15:00

Pluristem

15:20

Eric Shifrut, Tel Aviv University, Israel

CRISPR discovery platforms for engineered T cell therapies

15:40

Marcelo Erlich, Tel Aviv University, Israel

16:00

Adi Barzel, Tel Aviv Univervisty, Israel

In vivo B cell engineering

16:20

Dan Peer, Tel-Aviv University, Israel

The RNA revolution: from Gene Silencing to Gene Editing

16:40

Closing Remarks

17:00

Panel Discussion (Hybrid)

Gene delivery technologies for therapeutic applications

Moderated by Professor Dan Peer

Panelists: 

Mark A. Kay, Stanford University, USA

Ronit Satchi-Fainaro, Tel Aviv University, Israel

Laura Sepp-Lorenzino, CSO, Intellia

James McArthur, CEO, Pepgen

Patrick Baumhof, VP, RNA formulation in Curevac

Pete Lutwyche, CEO & President, Genevant